In patients with diabetes and high cardiovascular risk who participated in the ONTARGET/TRANSCEND (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomised Assessment Study in Angiotensin Converting Enzyme Inhibitor Intolerant Subjects with Cardiovascular Disease) trials, on-treatment SBP less than 120 mmHg was associated with higher risk for cardiovascular events and for death, but that study excluded patients with symptomatic heart failure [12]. The gene discussed is ACE; the disease is diabetes mellitus.